Quintiles ranks #1 in contract research revenues based on 1996 earnings estimates, CEO says.
Executive Summary
QUINTILES $517 MIL. REVENUES IN 1996 IS TOP IN CRO GROUP, Quintiles CEO Dennis Gillings maintained at Hambrecht & Quist's health care conference Jan. 7 in San Francisco. The total sales figure takes into account revenues generated from subsidiaries acquired during the year, including the Innovex peri-launch marketing organization, the medical device consultants BRI and the health policy firm Lewin. Corning's CRO spin-off, Covance, ranks second by 1996 revenue estimates, at about $490 mil.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth